Serine (Ser) proteases are enzymes that catalyze the hydrolysis of specific peptide bonds in their substrates, and one of the amino acids in the enzyme's active site is always a serine. The trypsin family and the subtilisin family are two families that have received particular attention in research. The process of blood clotting, protein digestion, cell signaling, inflammation, and protein processing are just a few of the numerous cellular and extracellular functions that serine proteases are essential for. A threonine residue is present in the active site of a family of proteolytic enzymes known as thronine (Thr) proteases. Although the catalytic subunits of the proteasome are the prototype members of this class of enzymes, the active site geometry and mechanism of acyltransferases were convergently evolved.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V71864 | Ongericimab (JS002) | 2145096-91-7 | Ongericimab (JS002) is a humanized anti-PCSK9 monoclonal antibody (mAb). |
|
V71896 | Patamostat mesylate (E-3123 mesylate) | 114568-32-0 | Patamostat (E-3123) mesylate is a potent protease inhibitor. |
|
V71907 | PCSK9-IN-1 | 2730022-10-1 | PCSK9-IN-1 is a new effective cyclic peptide PCSK9 inhibitor (antagonist) with Ki of 1.46 nM. |
|
V73403 | PCSK9-IN-10 | 368434-98-4 | PCSK9-IN-10 is a potent, orally bioactive PCSK9 inhibitor (antagonist) with IC50 of 6.4 µM. |
|
V83203 | PCSK9-IN-11 | PCSK9-IN-11 is a novel and potent PCSK9 inhibitor | |
|
V76654 | PCSK9-IN-11 | PCSK9-IN-11 (compound 5r) is an orally bioavailable PCSK9 inhibitor. | |
|
V73400 | PCSK9-IN-12 | 2455427-91-3 | PCSK9-IN-12 is a heteroaryl compound. |
|
V71879 | PCSK9-IN-13 | 2244129-23-3 | PCSK9-IN-13 (compound 3f) is a potent PCSK9 inhibitor that antagonizes low-density lipoprotein (LDL) receptor binding via binding to PCSK9, with IC50 of 537 nM. |
|
V71892 | PCSK9-IN-14 | 2913198-84-0 | PCSK9-IN-14 (compound Ia-8) is a potent PCSK9 inhibitor. |
|
V71888 | PCSK9-IN-15 | 2455423-94-4 | PCSK9-IN-15 (compound 5) is a potent inhibitor of protein convertase subtilisin/kexin 9 (PCSK9) (KD <200 nM). |
|
V71881 | PCSK9-IN-16 | 2455424-51-6 | PCSK9-IN-16 is a potent PCSK9 inhibitor. |
|
V71878 | PCSK9-IN-17 | 2455424-72-1 | PCSK9-IN-17 is a PCSK9 inhibitor. |
|
V71875 | PCSK9-IN-18 | 2455425-15-5 | PCSK9-IN-18 (compound 188) is a potent PCSK9 inhibitor (antagonist) with Kd of <200 nM[1]. |
|
V81053 | PCSK9-IN-19 | PCSK9-IN-19 (Compound 1) is a PCSK9 inhibitor. | |
|
V71899 | PCSK9-IN-2 | 2099167-44-7 | PCSK9-IN-2 is a novel small molecule inhibitor of PCSK9-LDLR protein-protein interaction (PPI) with IC50 of 7.57 μM. |
|
V71908 | PCSK9-IN-20 | 2929219-77-0 | PCSK9-IN-20 (Compound 3i) is a PCSK9 inhibitor (antagonist) with IC50 of 3.96 µM. |
|
V71901 | PCSK9-IN-22 | 2794203-47-5 | PCSK9-IN-22 (compound 29) is an orally bioactive PCSK9 inhibitor. |
|
V71865 | PCSK9-IN-3 | 2867496-34-0 | PCSK9-IN-3 is a novel and effective orally administered next-generation tricyclic peptide PCSK9 inhibitor. |
|
V78662 | PCSK9-IN-9 | PCSK9-IN-9 is a naturally derived isocoumarin. | |
|
V73398 | Pep2-8 | 1541011-97-5 | Pep2-8 is a PCSK9 inhibitor (antagonist) with Kd of 0.7 μM and IC50 of 1.4 μM. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
